Hyperproliferation and Parathyroid Neoplasia due to Genetic Variants by Ellis, La Shondra A
University of Connecticut
OpenCommons@UConn
Master's Theses University of Connecticut Graduate School
5-7-2016
Hyperproliferation and Parathyroid Neoplasia due
to Genetic Variants
La Shondra A. Ellis
University of Connecticut - Storrs, lashondra7674@gmail.com
This work is brought to you for free and open access by the University of Connecticut Graduate School at OpenCommons@UConn. It has been
accepted for inclusion in Master's Theses by an authorized administrator of OpenCommons@UConn. For more information, please contact
opencommons@uconn.edu.
Recommended Citation
Ellis, La Shondra A., "Hyperproliferation and Parathyroid Neoplasia due to Genetic Variants" (2016). Master's Theses. 912.
https://opencommons.uconn.edu/gs_theses/912
 Hyperproliferation and Parathyroid Neoplasia due to Genetic Variants 
 
 
 
La Shondra Ellis 
B.A., B.S., Oakwood University, 2014  
 
A Thesis 
Submitted in Partial Fulfillment of the    
Requirements for the Degree of  
Masters of Science  
At the 
University of Connecticut 
 2016 
 
 
 
 
 
 ii 
APPROVAL PAGE 
Master of Science Thesis 
Hyperproliferation and Parathyroid Neoplasia due to Genetic Variants 
 
 
Presented by 
La Shondra Ellis B.A., B.S. 
 
 
Major Advisor______________________________________________ 
Andrew Arnold 
 
Associate Advisor___________________________________________ 
Jessica Costa 
 
Associate Advisor___________________________________________ 
Anne Delany 
 
Associate Advisor___________________________________________ 
Marc Hansen 
 
 
 
 
 
 
 
 
 
University of Connecticut 
 2016 
 
 
 
 
 
 iii 
 
 
 
 
Table of Contents 
 
Acknowledgements ………………………………………………………………...V 
 
Abstract ………………………………………………………………………………VIII 
 
Background 
 
I. Calcium Homeostasis………………………………………………………….......1 
 
II. Basic Tumor Biology………………………………………………………...........2 
A. Tumorigenesis………………………………………………………………......2 
B. Clonality……………………………………………………………...................3 
C. Tumor Genes……………………………………………………………...........3 
 
III. Hyperparathyroidism……………………………………………………..............4 
A. Familial Hyperparathyroidism…………………………………………............4 
B. Sporadic Hyperparathyroidism………………………………………………...5 
 
IV. Aims and Objectives……………………………………………………….........10 
 
Chapter 1. Optimization of a Protocol for DNA Extraction from Formalin 
Fixed Paraffin Embedded Tissue …………………………………………………11 
     A. Introduction……………………………………………………………………...11 
     B. Materials and Methods………………………………………………………...12 
     C. Results ……………………………………………………..............................15 
     D. Discussion………………………………………………………......................20 
 
Chapter 2. Mutational Analysis of ZFY in Sporadic Parathyroid 
Adenomas……………………………………………………………........................21 
     A. Introduction……………………………………………………………..............21 
     B. Materials and Methods………………………………………………………....22 
     C. Results ……………………………………………………………....................24 
     D. Discussion……………………………………………………………...............26 
 
 
 
 iv 
 
Chapter 3: CDKI Mutational Analysis……………………………………….........29 
     A. Introduction……………………………………………………….....................29 
     B. Materials and Methods………………………………………………………...30 
    C. Results ……………………………………………………………....................30 
     D. Discussion……………………………………………………………...............31 
4. List of Abbreviations……………………………………………………………..33 
5. Bibliography……………………………………………………………................35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
 
 
Acknowledgements 
 
 
Principal Investigator  
Dr. Andrew Arnold of the Center of Molecular Medicine at University of 
Connecticut Health has been my mentor and advisor for the last two years. I 
sincerely appreciate the guidance and mentorship he has generously offered 
over the years.  Dr. Arnold always left his door open to any questions about my 
research and made himself available whenever I needed advice. He has fostered 
opportunities that allowed me to contribute to exciting research, travel, and 
scientific meetings.   
Lab Mates    
  I would also like to thank the members of the Arnold Lab. I enjoyed the 
rich scientific dialogues and the learning experiences that we shared. I spent 
countless hours in the lab with Justin Bellizzi, Kelly Brewer, Dr. Jessica Costa, 
and Robert Romano.  Every member of the lab has been invaluable, as they 
each enhanced my experience. I am particularly grateful for their willingness to 
offer advice and assistance when I needed to be steered in the right direction.  I 
especially want to give a special thank you to Dr. Costa for all the guidance and 
mentorship she has offered in the laboratory. 
I would also like to acknowledge Dr. Tobias Carling of Yale University for 
sending a cohort of 81 DNA samples from male patients with parathyroid 
adenomas. This donation was essential for my research as it enhanced our 
 
 
 
 vi 
sample pool and ultimately our understanding of ZFX and ZFY’s contribution to 
primary hyperparathyroidism. 
Thesis Committee 
I would also like to thank my thesis committee and the experts who were 
involved in the validation survey for this research: Jessica Costa, D.M.D., Ph.D., 
Anne Delany, Ph.D. and Marc Hansen, Ph.D. Their input and support was 
essential for the completion of my thesis. Without their passionate participations 
and input, the validation survey could not have been successfully conducted.  
Young Innovative Investigator Program 
Most importantly, I would like to thank Connecticut Institute for Clinical and 
Translational Science and their supportive staff for this opportunity to gain 
research experience as I earned my Master’s degree in Biomedical Science.   
I would like to thank Cato Laurencin, M.D., Ph.D., and Chief Executive 
Officer of the Young Innovative Investigator Program (YIIP) for developing a 
program that provides tools to students, like myself to succeed in medicine.  I 
also want to thank Linda Barry, M.D., and Chief Operating Officer of YIIP. She 
has played a vital role in YIIP and has been an exceptional professional model. I 
deeply appreciate her strong advocacy for my fellow YIIP colleagues and me.   
Lana Angelo has played many roles in the YIIP program while serving as 
the program’s coordinator. I especially want to recognize Lana for being 
someone who not only made sure we were thriving academically and 
professionally, but also in our personal lives as well.  I am so grateful for her care 
and genuine willingness to invest in my success. 
 
 
 
 vii 
I extend my utmost gratitude to my mentor Elaine Choung-Hee Lee, Ph.D. 
for the time she has invested in me while earning my master’s in Biomedical 
Science. I am amazed by her dedication to my success, I will forever be grateful 
for the support and encouragement I have received from her over the years. I 
consider it a blessing that I was paired up with a mentor like Dr. Lee. While 
working towards my professional and personal goals. 
Friends and Family 
Finally, I must express my very profound gratitude to my parents 
Hendrena Martin and George Ellis  and my family members Yolanda Johnson, 
Ron Johnson, and Margaret Martin. They have continuously supported me by 
providing me with unfailing support and continuous encouragement throughout 
the years. This accomplishment would not have been possible without them. 
I would also like to acknowledge Ailiana Denis from Depaul University’s 
Communications Department as the second reader of this thesis. I am indebted 
to her for her very valuable comments on my thesis.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 
 
 
 
 
 
Abstract 
 
Primary Hyperparathyroidism (PHPT) is a common endocrine disorder, 
which is seen at all ages, but primarily in post-menopausal women. While 
commonly asymptomatic, clinical manifestations include kidney stones, 
osteoporosis, and other symptoms. Parathyroid adenomas are the most common 
cause of PHPT (85%), followed by hyperplasia (15%) and carcinomas (~1%). 
Established genes associated with sporadic parathyroid adenomas include: 
proto-oncogene cyclin D1 (PRAD1, CCND1), tumor suppressor gene MEN1, and 
several cyclin-dependent kinase inhibitor genes CDKN2B, CDKN2C, CDKN1A, 
and CDKN1B. Recently, compelling genetic evidence implicated that the ZFX 
gene, part of the Kruppel C2H2 type zinc finger protein family, is a likely 
parathyroid adenoma oncogene. It was found to be involved in almost 5% of all 
cases (Soong & Arnold, 2014).  
Genetic analysis is essential to this study, and the quality of the DNA used 
is crucial in further analyses. Formalin-Fixation and Paraffin-Embedding (FFPE)  
is commonly practiced preservation method, which  unfortunately sacrifices the 
quality of the DNA obtained from each sample.  This is why it is imperative to 
optimize a protocol that yields the most DNA, without introducing further 
degradation. We tested multiple protocol modifications and determined that the 
modified Qiagen Kit protocol, using Qiagen deparaffinization solution, with one-
 
 
 
 ix 
hour proteinase K incubation yielded optimal DNA concentrations and the least 
amount of protein degradation.  
With the discovery of ZFX as a candidate parathyroid oncogene, the 
potential involvement of the highly homologous gene, ZFY, came to light. Since 
analogous mutations in ZFY could have similar tumorigenic effects as those in 
ZFX, we analyzed the entire coding region of ZFY in sporadic parathyroid 
adenomas from male patients. This region was PCR-amplified and Sanger 
sequenced in 117 adenomas. One novel variant c.1402C>T was found, resulting 
in a predicted histidine to tyrosine change at position 468 of the ZFY protein. This 
variant may have a role in the molecular pathogenesis of sporadic parathyroid 
adenomas. Grasping the full understanding of the biology of ZFX and ZFY’s 
mutations in the context of parathyroid tissue will further illuminate the 
pathogenesis of parathyroid neoplasms. 
In addition to involvement in sporadic parathyroid adenomas, recent 
studies have also suggested that germline mutation in several CDKIs can cause 
sydromic HPT (Pellegata et al 2006), with phenotypic presentation similar to  
multiple endocrine neoplasia type 1 (MEN1). A patient diagnosed with 
prolactinoma and familial hyperparathyroidism was referred for mutational 
analysis of CDKIs p15, p18, p21, and p27. Mutational analysis of four CDKI 
genes identified one novel variant, c.34G>A, in CDKN2C, encoding p18. We 
believe this variant may contribute to the molecular pathogenesis of the patient’s 
familial hyperparathyroidism and prolactinoma.  
 
 
 
 x 
In order to understand hyperproliferation and parathyroid neoplasia, an 
inclusive study to optimize methodology for DNA extraction from FFPE samples 
and, mutational analysis of ZFY, ZFX, and CDKIs was performed. The overall 
findings of this project may suggest that ZFY or CDKIs mutations contribute to 
the development of hyperparathyroidism. 
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I. Calcium Homeostasis 
Calcium is essential to most mammalian cellular functions. Serum calcium 
levels are maintained by the parathyroid gland, which is the master regulator of 
calcium homeostasis, through regulated secretion of parathyroid hormone (PTH). 
Under normal physiological conditions, subtle decreases in blood calcium levels 
stimulate the secretion of PTH, which in turn stimulates the increase of serum 
calcium through effects on the gastrointestinal, renal, and skeletal systems. This 
stimulation increases calcium absorption, as well as the mobilization of 
mineralized calcium in the bone, and decreases calcium excretion. The resulting 
elevation in serum calcium levels feed back on the parathyroid glands to 
decrease PTH secretion (Figure 1).  
Primary hyperparathyroidism (PHPT) is a common endocrine disorder, 
with its highest incidence in post-menopausal females (Marcocci and Cetani 
2011). Patients with primary hyperparathyroidism exhibit hypercalcemia with an 
unsuppressed parathyroid hormone level. While primary hyperparathyroidism is 
generally asymptomatic in the western world, marked hypercalcemia can lead to 
gastrointestinal symptoms, bone problems such as osteoporosis and osteitis 
fibrosa cystica, effects on the central nervous system, and kidney stones.  
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Figure 1. Calcium Homeostasis 
The parathyroid glands function to produce PTH in response to low serum 
calcium. PTH acts on the kidneys, bones and intestines. All three target 
organs work together to increase serum calcium levels, which then feedback 
on the parathyroid glands, shutting down PTH production. In primary 
hyperparathyroidism, this feedback loop is lost, and this leads to uncontrolled 
PTH secretion and elevated calcium levels. 
 
II. Basic Tumor Biology 
A. Tumorigenesis 
  Tumors are caused by genetic mutations triggering uncontrolled 
cell proliferation. Gene mutations are typically categorized as either somatic or 
germline mutations. Somatic mutations can occur in any of the cells of the body 
except the germ cells (sperm and egg) and therefore are not passed on to 
children (Rati, 2011). In contrast, germline mutations can be passed on to some 
or all progeny. Somatic mutations can be represented in a sector of identical cells 
from a single progenitor cell or phenotypically represented as a dominant 
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mutation that typically occurs after the organism has fully developed (Li, 2004). 
Mutations that occur in germline tissue happen at fertilization or during the 
process of development in sex cells. Familial syndromes stem from germline 
mutations that are transmitted to offspring and are present in every cell. When a 
mutation gives a selective advantage to a cell, leading to a clonal outgrowth, it is 
considered a driver mutation. Alternatively, passenger mutations have no effect 
on the fitness of a cell but may be associated with a clonal expansion. Neoplasia 
or abnormal cell growth may be malignant or benign. Malignant tumors are 
invasive with rapid growth, while benign adenomas are slow growing non-
invasive tumors that do not metastasize.  
B. Clonality 
The term clonality is related to understanding the cell of origin giving rise 
to daughter cells. Monoclonality refers to daughter cells arising from a single cell, 
while polyclonality refers to cells proliferating from multiple progenitor cells. 
Clonality can be assessed with molecular analysis. In female patients, tumor 
clonality can be evaluated with X chromosome inactivation assays, based on the 
concept that in every female cell, one X chromosome becomes inactivated and 
the pattern of which chromosome becomes inactivated is random (Brown CJ et al 
2000).  
C. Tumor Genes  
Mutations in tumor suppressor genes play a role in the pathogenesis of 
cancer, whether it is complete or partial tumor suppressor inactivation (Berger et 
al 2011). Oncogenes are activated by mutation, gene amplification, or 
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chromosome rearrangements that contribute to the development of a neoplastic 
phenotype. There are two classes of oncogenes one lowers the requirements for 
growth factors leading to a change in the cells phenotype, while the other class 
saves cells from apoptosis.  
 
III. Hyperparathyroidism 
Hyperparathyroidism is a biochemical diagnosis in which excessive 
secretion of PTH leads to high blood calcium. Discerning if a patient should be 
diagnosed with primary or secondary hyperparathyroidism relies on the 
biochemical differences of high and low calcium levels, respectively. There are 
two forms of primary hyperparathyroidism, sporadic and familial. 
A. Familial Hyperparathyroidism 
Familial hyperparathyroidism can be diagnosed based on a family history 
of PHPT or other features suggestive of a familial multiple endocrine neoplasia 
syndrome. Inherited (familial) syndromes account for ~5% of Primary 
Hyperparathyroidism (PHPT) (Pepe J et al 2011).   
The multiple endocrine neoplasia term is based on two or more endocrine 
glands producing tumors. Depending on the pattern of the benign or malignant 
tumors, it is characterized as one of the several distinct syndromes, which are 
summarized in Table 1. MEN1 is characterized by tumors in the endocrine 
pancreas, pituitary, and most commonly in the parathyroid. This syndrome is 
caused by mutations in the MEN1 gene (70-95%) of cases or cyclin dependent 
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kinase inhibitor genes (CDKIs) p15 (1%), p18 (0.5%), p21 (0.5%), p27 (1.5%) 
(Marini F 2008). 
MEN2 is caused by mutations in the RET gene and is further divided into 
two different subtypes: MEN2A and MEN2B. MEN2A causes medullary thyroid 
cancer, pheochromocytoma, and adenomas in the parathyroid. MEN2B causes 
medullary thyroid cancer, marfanoid habitus/ mucosal neuroma, and 
pheochromacytoma. MEN4 shares the same phenotypic presentation as MEN1, 
however MEN4 is caused by mutations in the CDKN1B (p27) gene (Table 1). 
 
Table 1. Multiple Endocrine Neoplasia Syndromes 
Syndrome Gene Manifestations 
MEN1 MEN1 Pituitary Adenoma, 
Parathyroid Neoplasia, 
and Pancreatic Tumors 
MEN2A RET Parathyroid Neoplasia, 
Medullary Thyroid 
Carcinoma, and 
Pheochromacytoma 
MEN2B RET Mucosal Neuromas 
Marfanoid Habitus, 
Medullary Thyroid 
Carcinoma, and 
Pheochromacytoma 
MEN4 (MENX) CDKN1B Pituitary Adenoma 
Parathyroid Neoplasia, 
and Pancreatic Tumors 
 
B. Sporadic Hyperparathyroidism 
There are three ways for sporadic, primary hyperparathyroidism to 
manifest: parathyroid adenomas are most common (85%), parathyroid 
hyperplasia is less common (15%), and rarely, parathyroid carcinoma can occur 
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(<1%) (Loya SolIs 2014). There are a few established tumor genes including 
cyclin D1 (CCND1/PRAD1) and multiple endocrine neoplasia type 1 (MEN1) 
(Costa-Guda,,2014). Candidate oncogenes include β-Catenin (CTNNB1), 
Enhancer Of Zeste 2 Polycomb Repressive Complex 2 subunit (EZH2), and Zinc 
Finger Protein X-linked (ZFX) (Duan K 2015). The frequencies of various gene 
mutations identified in sporadic parathyroid adenoma are illustrated in Figure 2.  
 
Figure 2. Genetic Abnormalities in Sporadic Parathyroid Adenomas  
MEN1 is the most frequently mutated gene in sporadic parathyroid adenomas. 
Rearrangements of cyclin D1 and intragenic point mutations of CDKI genes have 
also been identified as genetic drivers. Rarely, mutations occur in other genes, 
such as β-Catenin (CTNNB1) and EZH2.   
 
CCND1/PRAD1, which encodes cyclin D1, was first identified as a human 
oncogene based on its involvement in parathyroid tumors (Motokura T., Arnold, 
1991). Overexpression of cyclin D1 is seen up to 40% of sporadic parathyroid 
tumors. Cyclin D1 gene rearrangements seen in up to 8% of tumors directly 
causes this overexpression. Cyclin D1 gene rearrangement is a pericentromeric 
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inversion of chromosome 11 that is well characterized, which places the 5' PTH 
regulatory region upstream of the cyclin D1 gene, as shown in Figure 3. 
 
Figure 3. CCND1/PRAD1 gene rearrangement 
A schematic of the pericentromeric inversion of chromosome 11. This 
rearrangement places the 5' PTH regulatory region upstream of the cyclin D1 
gene.  
 
Cyclin D1 is a regulator of the subunits CDK4 and CDK6  these 
complexes are critical for the progression of the cell cycle, specifically during the 
G1 phase (Figure 4). Cyclin dependent kinases (CDKs) and cyclins bind together 
to promote the continuation of the cell cycle, while cyclin dependent kinase 
inhibitors (CDKIs) are put in place to counteract cell proliferation. In the early G1 
phase, cyclin dependent kinase 4 and 6 are associated with cyclin D. Later in the 
G1 phase, after the restriction point, CDK2/ cyclin E complex stimulates the 
transition of the cell cycle from G1 to S phase, which determines cell division. 
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The combined CDK 2/ cyclin A complex governs the S phase entry, initiating 
DNA replication. The cell is then committed to proliferate with the cyclin B and 
CDK1 complexes activating mitosis.  
Mutations in several CDKI genes, including p27, have recently been 
identified as important contributors to a subset of parathyroid adenomas. 
Mutations have been identified in a few additional candidate genes, but, to date, 
their ability to drive parathyroid tumorigenesis experimentally has not been 
demonstrated. Mutations in β-catenin and EZH2 appear very rarely in parathyroid 
adenomas. In contrast, mutations in ZFX appear to be more common.  
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Adapted from Donavan J. et. Al. 2000 
Figure 4. Cell Cycle Control 
The cell cycle displays the four phases; cell growth (G1), DNA synthesis (S), cell 
growth (G2), and mitosis (M). Progression through the cell cycle is governed by 
interactions between Cyclins, CDKs and CDKIs  
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Aims and Objectives 
The overall aim of this dissertation was to further the understanding of genetic 
events that lead to parathyroid hyperproliferation and neoplasia. This was done 
through the following specific aims: 
1. To optimize a protocol for DNA extraction from formalin fixed paraffin 
embedded tissue.  
An optimized protocol for DNA extraction from formalin fixed paraffin embedded 
(FFPE) tissue is essential for further analysis of genetic events promoting 
parathyroid neoplasia. To this end, we tested several different protocol 
modifications that produce the highest DNA yields while minimizing degradation.  
2. To determine the role of ZFY in sporadic parathyroid adenomas. 
Recurrent, somatic mutations in the ZFX gene have recently been identified in 
parathyroid adenomas. Since ZFX and another gene, ZFY, are virtually identical, 
we hypothesized that parathyroid adenomas may contain mutations in the ZFY 
gene, similar to those observed in ZFX. To test our hypothesis, we directly 
analyzed the entire coding region of ZFY in parathyroid adenomas from male 
patients.  
3. To perform CDKI mutational analysis in a patient with unexplained MEN1. 
A patient with phenotypic MEN1 (prolactinoma and familial 
hyperparathyroidism), but negative for MEN1 gene mutation was referred to us 
for Cyclin Dependent Kinase Inhibitor gene sequencing, in order to bring clarity 
for genetic counseling. 
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Chapter 1. Optimization of a Protocol for DNA Extraction from Formalin 
Fixed Paraffin Embedded Tissue  
Introduction 
Tissues are commonly fixed in formalin and embedded in paraffin for 
histopathological diagnosis and preservation after biopsies or surgeries. Formalin 
fixation and paraffin embedding is invaluable for the purpose of preserving tissue 
for long-term storage and later pathological studies. Fixation is one of the most 
vital steps in the preservation process. As illustrated in Figure 5, formalin cross-
links amino acids in proteins and nitrogen molecules in nucleic acids to prevent 
tissue decay by autolysis or putrefaction. Unfortunately, in comparison to 
preservation by quickly freezing tissue, the formalin fixation process decreases 
the quality of the nucleic acids that can be extracted from the tissue. Therefore, 
optimizing a protocol for DNA extraction from formalin-fixed, paraffin-embedded 
(FFPE) tissue is crucial for gaining higher DNA yields without increasing 
degradation. 
Extraction of DNA from FFPE tissues requires removal of the paraffin wax 
(deparaffinization), cell lysis releases proteins and nucleic acids, proteinase K 
digestion to remove contaminating proteins and inhibit nuclease activity, and 
purification through a DNA-binding column or other methods. To develop an 
optimized protocol for DNA extraction from FFPE tissue, we tested two different 
deparaffinization methods, modifications to the proteinase K digestion time and 
elution protocol, using column-based DNA purification.  
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Adapted from Qiagen QIAMP DNA FFPE Tissue Handbook 2012 
Figure 5. Formalin Fixation Effects  
Crosslinking between proteins and nucleic acids are caused by formalin fixation. 
This figure represents how prolonged fixation induces crosslinking. 
 
Materials and Methods 
Deparaffinization 
Extracting DNA from paraffin blocks begins with slicing tissue with a 
microtome into sections of 20 μM. The deparaffinization procedure in this 
experiment used two different methods: either xylene-ethanol or 
Deparaffinization Solution (Qiagen).  
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 Deparaffinization with xylene-ethanol is done under the hood to minimize 
exposure to hazardous fumes. The tissue section is soaked in 1 mL of xylene for 
10 minutes, and then centrifuged for 30 seconds. This step is followed by 
saturating the tissue in 1 mL of 100% ethanol for 10 minutes and centrifuged 
again for 30 seconds. This process of xylene and ethanol is repeated in a second 
cycle. After the cycles are completed, the sample must be dried at room 
temperature. Tested modifications to the xylene-ethanol deparaffinization 
protocol include preheating xylene to 65°C, chilling the ethanol to 4°C, and 
increasing the number of cycles. 
Deparaffinization with Qiagen Deparaffinization Solution is done by incubating 
the tissue section with 320 μL of Deparaffinization Solution at 56°C for either 
three or eight minutes. 
Proteinase K Digestion 
 Following deparaffinization, the tissue was incubated with proteinase K 
in the presence of ATL lysis buffer. Incubations were done for either one hour, 90 
minutes, or overnight. 
Column Purification 
DNA was purified using the QIAamp DNA FFPE Kit, following the 
manufacturer-recommended protocol. Modifications tested included using chilled 
ethanol or increasing the incubation time with the AE elution buffer from 5 to 10 
minutes.  A summary of all protocol modifications is shown in Table 2. 
Analysis of DNA Quality and Yield 
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The amount of DNA degradation was analyzed using gel electrophoresis 
and imaging. DNA quality and yield were further analyzed using a Nanodrop 
2000c and Qubit fluorometer.  The Nanodrop is used to quantify DNA via 
spectrophotometry. Nucleic   acids   absorb   light   at   a   wavelength   of 
  260  nm, the 260/280 and 260/230 ratios measure different characteristics.  
The 260/280-ratio measures purity of DNA and RNA; the optimal range for DNA 
is 1.7-2.0 ratios above 2 suggest the presence of RNA, while a ratio lower than 
1.7 suggest contamination with phenol, protein, or EDTA. The 260/230 ratio 
represents pure DNA at a score that ranges from 2.0-2.2. A score that is lower 
than this range may reveal contamination of carbohydrates, phenol, or EDTA.  
The Qubit fluorometer can quantify DNA, RNA, and protein using different 
fluorescent dyes. Each dye is specific for one type of molecule: DNA, RNA or 
protein. The Qubit is generally more precise in determining the DNA 
concentration but cannot simultaneously give information about RNA or protein 
contamination. 
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Table 2. Formalin Fixed Paraffin Protocol Embedded Protocol 
Protocol Qiagen Xylene-Ethanol 
 
Deparaffinization 
Original 
 
Incubate at 56°C-3 min, 
Cool at (15-25°C) 
 
1 ml 100% EtOH 10 min (2x’s) 
Centrifuge at Max 1 min 
1 mL 100% EtOH 10 min (2X’s) 
Dry at room temperature 
 
 
Deparaffinization Method 
Modified 
 
Incubate at 56°C-8 min 
 Cool at (15-25°C) 
 
Preheat: Xylenes 65°C 
Chill: Ethanol 4°C 
1 mL 100% EtOH 10 min (5X’s) 
Dry at room temperature 
 
Proteinase K Incubation 
Original 
1 Hour 1 Hour 
 
Proteinase K Incubation 
Modified 
1 Hour 
90 Minutes 
Overnight 
1 Hour 
90 Minutes 
Overnight 
 
Column Purification 
Original 
 
Add AL Buffer 200L  Add EtOH 200 μL 
Centrifuge QI amp Column AW1 500 μL  
 AW2 500 μL  25 μL AE Buffer 5 min 
 
 
Column Purification 
Modified 
 
Add AL Buffer 200 μL > Add chilled EtOH 200 μL 
Centrifuge QI amp Column  AW1 500 μL 
 AW2 500 μL  25 μL at AE Buffer -10 min 
 
Results  
Five different protocols, include two distinct approaches of 
deparaffinization were tested. The first comparison explored the two different 
deparaffinization methods, using an overnight proteinase K digestion and the 
manufacturer-recommended QIAamp DNA FFPE Kit (“original”) protocol (Figure 
6). The xylene-ethanol method (designated A) demonstrated consistently high 
levels of DNA degradation across all four tumors. In comparison, the Qiagen 
Deparaffinization method (designated B) showed less degradation. However, the 
xylene-ethanol method gave higher DNA yields. 
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/ 
Figure 6. Original Protocol with Overnight Proteinase K Incubation  
A. Lower levels of DNA degradation were noted with the xylene-ethanol method 
as compared to the Qiagen method when using the original protocol with 
overnight proteinase K digestion.  
B. The xylene-ethanol method also produced greater DNA yield.  
 
The second comparison explored the two different deparaffinization 
methods, using a shorter, one-hour, proteinase K digestion and the 
manufacturer-recommended QIAamp DNA FFPE Kit (“original”) protocol (Figure 
7). In this experiment, the Qiagen Deparaffinization method consistently showed 
less degradation across samples and much higher (up to 3x) DNA yields. 
A  
A 
 
B 
A 
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Figure 7. Original Protocol with One Hour Proteinase K Incubation  
A. Lower levels of DNA degradation were noted with the Qiagen method as 
compared to the xylene-ethanol method when using the original protocol with 1-
hour proteinase k digestion.  
B. The Qiagen method also produced greater DNA yield. 
 
The third comparison explored the two different deparaffinization methods, 
using a one-hour proteinase K digestion but with modifications to the 
manufacturer-recommended QIAamp DNA FFPE Kit (“modified”) protocol (Figure 
8). The modifications included using chilled ethanol and increased incubation 
time with the elution buffer. For the xylene-ethanol method, the number of cycles 
was also increased from two to five cycles. In this experiment, the Qiagen 
deparaffinization method demonstrated significantly lower degradation with 
higher DNA yields.  
B 
A 
 
A 
A 
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Figure 8. Modified Protocol with One Hour Proteinase K Incubation  
A. Lower levels of DNA degradation were noted with the Qiagen method as 
compared to the xylene-ethanol method when using the modified protocol with 1-
hour proteinase K digestion.  
B. The Qiagen method also produced greater DNA yields quantified by Nanodrop 
and Qubit. The modified protocol with 1-hour proteinase K Incubation 
demonstrated the best DNA yields out of all the observed protocols. 
 
The fourth comparison explored the two different deparaffinization 
methods, using an overnight proteinase K digestion and with modifications to the 
manufacturer-recommended QIAamp DNA FFPE Kit (“modified”) protocol (Figure 
9). Again, the xylene-ethanol method demonstrated consistently higher 
degradation and consistently lower DNA yields. 
A  
A 
 
 B 
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Figure 9. Modified Protocol with Overnight Proteinase K Incubation 
A. Lower levels of DNA degradation were noted with the Qiagen method as 
compared to the xylene-ethanol method when using the modified protocol with 
overnight proteinase k digestion.  
B. The Qiagen method also produced greater DNA yield. 
 
The fifth and final comparison explored the two different deparaffinization 
methods, using a 90-minute proteinase K digestion and with modifications to the 
manufacturer-recommended QIAamp DNA FFPE Kit (“modified”) protocol (Figure 
10). Again, the Qiagen deparaffinization method demonstrated lower degradation 
with higher DNA yields. However, the DNA yields in this experiment were lower 
than in most other experiments. 
 
 
 
 
A  
A 
 
  
B 
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Figure 10. Modified Protocol with 90 Minute Proteinase K Incubation 
A. Lower levels of DNA degradation were noted with the Qiagen method as 
compared to the xylene-ethanol method when using the modified protocol with 
90 minute proteinase K digestion.  
B. The Qiagen method also produced greater DNA yield.  
 
Overall, the method that appeared to produce the highest DNA yields with 
the lowest amount of DNA degradation was the Qiagen deparaffinization method, 
using a one-hour proteinase K digestion and with modifications to the 
manufacturer-recommended QIAamp DNA FFPE Kit protocol. 
 
 
 
 
 
A 
 
A 
 
  
B 
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Discussion 
Narrowing down an optimized protocol that effectively isolates DNA rom 
FFPE samples is beneficial since this has been a challenge in the research 
community. There were several considerations to account for when it came to 
maintaining the integrity and the yields of the sample. After observing different 
FFPE protocols incorporating modifications to the deparaffinization, proteinase K 
incubation, and elution stages. It appears that the modified protocol with one-
hour proteinase K incubation using the Qiagen kit solution yielded the best 
results for DNA preservation.  
The previous thoughts were that the xylene-ethanol method with 
modifications and an overnight incubation of proteinase K would work best for 
producing the best DNA yields. However, it appears that the longer the 
proteinase K incubation was, the lower the results for the DNA yield appeared. It 
also seems that the increased cycles of xylene boosts the levels of degradation. 
Although xylene-ethanol protocols have been frequently practiced, a more bio-
friendly solvent for deparaffinization may be preferred, like the Qiagen kit offers.  
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Chapter 2. Mutational Analysis of ZFY in Sporadic Parathyroid Adenomas 
Introduction 
Recently, compelling genetic evidence was reported implicating the Zinc 
Finger protein gene encoded by the X-chromosome (ZFX), a member of the 
Kruppel C2H2 type zinc finger protein family, as a likely parathyroid adenoma 
oncogene involved in almost 5% of cases (Soong, Arnold 2014). Recurrent 
somatic mutations in ZFX were strikingly specific, focused on a hotspot of two 
consecutive highly conserved arginine residues in the most C-terminal zinc finger 
domain of the protein. ZFX is situated on the X-chromosome but escapes X-
inactivation and is thus transcribed from both alleles in females. In males, the 
highly homologous Zinc Finger protein gene encoded by the Y-chromosome 
(ZFY) is expressed and provides dosage compensation. ZFX and ZFY are highly 
homologous; in fact overall they are 92% identical, and while the zinc finger 
domains are 97% identical. ZFY, like ZFX is a part of the Kruppel C2H2 type zinc 
finger protein family. ZFY is a transcriptional activator that binds to the 
consensus sequence 5'-AGGCCY-3'. There is very little known about ZFY, 
however it is involved in multicellular organismal development, and has thirteen 
zinc finger domains involved in nucleic acid binding (Lova-Solis 2014). 
Since analogous mutations in ZFY could have similar tumorigenic effects 
as those in ZFX, and with one such ZFY mutation already noted in a colon 
carcinoma (COSMIC), we analyzed ZFY in a series of typical sporadic 
parathyroid adenomas from male patients.  
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Methods 
Patients and Samples 
Tumor samples were retrieved from patients that received a 
parathyroidectomy under the circumstances of managing primary 
hyperparathyroidism. Samples were collected from solely sporadic related cases. 
This is based on negative family history related to primary hyperparathyroidism, 
and multiple endocrine neoplasia. Every tumor sample had both the tumor and 
matched germline control DNA for every designated patient. All samples were 
obtained with informed consent in accordance with institutional review board-
approved protocols. 
PCR and Sanger Sequencing 
Primers were designed for ZFY’s seven coding exons (Table 3). Primers 
were designed so that intron regions at the splice junctions were also examined 
(Figure 11). The PCR reactions were carried out in 20 μL reaction volumes, 
containing 25 ng of sample DNA, 12 μL of deionized H2O, 2 μL of 10X PCR 
Buffer, 10 μM of dNTPs, 50 mM of MgCl2,, 1 μL of forward and reverse primer, 
and 1 μL of Taq Gold (Applied Biosystems, Foster City, CA, USA). The thermal 
cycles began with cycling conditions for exons 2-8. The PCR reactions were 
performed by incubating at 95°C for 10 minutes, followed by 35 cycles of 95°C 
for 30 seconds, 55°C for 30 seconds (60°C for exon7) and 72°C for one minute, 
and a final elongation step of 72°C for 10 minutes. 
 
 
 
 
 
 24 
Table 3.  ZFY Primer Design List 
 
 
Figure 11. ZFY gene Primers 
All the coding regions (exons 2-8) were PCR amplified. The 13 zinc fingers are 
included in Exon 8. 
 
 The PCR products were purified with ExoSAP-IT (Affymetrix, Santa Clara, 
CA) and were sequenced using standard Sanger sequencing methodology 
Exon Forward Reverse Expected 
Product Size 
(BP) 
1 AGAGAAAGGCCGTCCTGCAGC CTTCGCGGACATTTACATAGC 360 
2 CCCATGTATCCCTGGAAATC 
 
CCCATGTATCCCTGGAAATC 
 
446 
3(pt.1) GAGGAACACCAAGGACATAG 
 
TTCTGGCATAGACATTGAGG 
 
400 
3(pt.2) CAAGTGCTGGACTCAGATGT 
 
TGTTAGAAAACACAGGTTTC 
 
295 
4 AACAAAGATGACATATGTCC 
 
CATTTGGTTGAAACATTTGG 
 
342 
5 ATACACTAAAACGTGTAAGC TGATGGGTTGATAGGTGCAG 278 
6 CTGTGTGATCTCTGTAAACC AGAAACCACTTTCAACAGTG 297 
7 TGTCATTCATGAGTGTCAGG AATACATGTGGCCTACTAGC 441 
8(a) ATTCATGAGGAGACCAGAAG GAGGTGGCGATTCAATAACC 493 
8(b) AAAAGGGGCCAACAAAATGC TTCTGAAGGCCTGTGAAAGC 454 
8(c) CACATCAGTGTTTGCATTGC TCTGCTTCAAGGCCAACATC 431 
 
8(d) 
 
ACCTTCAGAAAAGAACCAGC 
 
GGCCTGTGAAAGCCTTTCTCG 
 
362 
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(GeneWiz Inc., South Plainfield, NJ). Sequence data were analyzed using the 
Sequencher DNA sequence analysis software to align multiple tumor sample 
sequences along with reference sequences and to analyze possible variants in 
the tumor and control samples. Potential mutations were confirmed by a second 
cycle of sequencing from independent PCR reactions and by sequencing the 
DNA from the blood sample, to check for germline variants. 
Results  
A total of 117 parathyroid adenomas were tested for sequence variants in 
the coding region of ZFY. If the true frequency of ZFY mutation in parathyroid 
adenoma was comparable to that of ZFX (6/130, 4.6%), this sample size of 117 
was sufficiently powered to detect such mutations, with a statistical power of 80% 
(Table 4). 
 
Table 4. Statistical Power Calculation 
Power Calculation ZFX ZFY 
Sample Size 130 117 
Average Value 6 5 
(Expected Value) 
Statistical Power 80% 
 
Out of 117 cases, two variants were found (one still unconfirmed), each 
represented in two different patients.  The variants include one single nucleotide 
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polymorphism and one point mutation. The single nucleotide polymorphism 
(rs111915341) was found in the intron region preceding exon 5 (Figure 12).  
 
 The novel variant, c.1402C>T, affects the first base of the codon, 
resulting in histidine to tyrosine change at position 468 of the protein, affecting 
the second zinc finger domain. Analysis of germline DNA suggested the variant 
was somatic but neither finding has yet been replicated and must be considered 
preliminary (Figure 13).  
 Two methods were used to determine any possible changes in 
functionality due to the variant. The first tool used was a software program called 
Polymorphism Phenotyping V2 (PolyPhen-2). With this tool, the histidine to 
tyrosine change at position 468 is predicted to have a probably damaging effect, 
with a score of 0.998 out of 1.0. This prediction was confirmed using a second 
 
Figure 12. ZFY Direct genomic DNA Sequencing of rs111915341 
The single nucleotide polymorphism (rs111915341) was found in the intron 
region preceding exon 5.  
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software tool, PROVEAN, which also forecasts the impact of a variant on the 
biological function of a protein. In this analysis, the default threshold is -2.5; 
variants with a score equal to or below -2.5 are considered “deleterious”. Variants 
with a score above -2.5 are considered “neutral”.  The PROVEAN score for the 
H468Y variant calculates it to be -3.068, suggesting it is deleterious. 
 
       
Figure 13. ZFY Direct genomic DNA Sequencing of C1402 mutation. 
A novel variant c.1402C>T was found in exon 8, the top chromatogram 
demonstrates the normal sequence.  
 
Discussion 
Interest in sequencing ZFY came from the finding of recurrent, somatic 
mutations of ZFX in parathyroid adenomas. While in ZFX, identified mutations 
targeted a hotspot of two consecutive, highly conserved arginine residues at 
positions 786 and 787 in the last zinc-finger domain. Sequencing the entire 
 
 
 
 28 
coding region was important to determine if there were any other mutations 
outside of the hot spot region that could contribute to parathyroid tumorigenesis. 
While no ZFY mutations had previously been identified in other endocrine 
tumors, COSMIC notes a ZFY R782 mutation (corresponding to ZFX R787) in 
colon cancer. With this knowledge in mind, ZFY was analyzed in a series of 
typical, sporadic parathyroid adenomas from male patients.  
One novel variant, c.1402C>T that remains to be replicated, was identified 
in one tumor. The base change results in a histidine into tyrosine change at 
position 468, altering it from basic to aromatic, yet still remaining polar. This is a 
non-conservative mutation, which likely has deleterious effects. The variant is 
found in the N terminal region where there are multiple C2H2 Zinc finger repeats.  
This region has been shown to activate transcription when fused to a DNA 
binding domain. This genetic alteration, if confirmed, would support the idea that 
ZFY, like ZFX, may function as a direct-acting oncogene in the context of 
parathyroid adenomas. 
Surprisingly, the chromatogram of variant c.1402C>T appears 
heterozygous, with two peaks representing the mutant thymine and the normal 
cytosine. This is a noteworthy finding because typically only one peak for a male 
patient would appear. The observed heterozygosity of the ZFY mutation may be 
due to contamination with non-tumor cells, mosaicism, or tumor heterogeneity. 
In mosaicism, subjects have an apparently heterozygous genotype due to 
the presence of two different cell populations. Mosaicism is due to mitotic errors 
during embryonic development. Mosaicism is rare, however there has been a 
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study that provides evidence that mosaicism can account for some sporadic 
cases of MEN1 (Klein R. 2004).  
In tumor heterogeneity, clonal evolution results from distinct genetic 
events that occur in the pathway from a normal cell into a tumor.  In this 
transformation, a normal cell is hit randomly by a genetic event.  This event 
causes a genetic modification that leads to a clonal, subpopulation of cells. 
These cells, unlike the normal cells, multiply more and die less often. Those 
same cells may be hit again and begin to further expand because they have a 
growth advantage over the previous cells.  
The entire coding region of ZFY was fully sequenced in 117 of these 
tumors, with one preliminary variant found with confirmation pending. The highest 
priority in future observations will incorporate replicating this variant to confirm 
this mutation. This study suggests experimental evidence for the new role of 
mutant ZFY as a possible parathyroid oncogene. It will also provide a framework 
for our subsequent studies to address the binding sites and target gene 
promoters crucial to ZFY’s oncogenic functions. Further, these studies of the 
mechanisms behind parathyroid adenoma development will help address crucial 
and more general questions on how benign and malignant growths differ and 
how that information might help in preventing human malignancies in multiple 
tissue contexts.   
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Chapter 3: CDKI Mutational Analysis 
Introduction 
The cyclin dependent kinase inhibitors (CDKIs) function as negative 
regulators of cell cycle progression. CDKIs are categorized into either the Cip/Kip 
or INK4 family. The cyclins that are a part of the Cip/Kip family include p21 
(encoded by CDKN1A), p27 (CDKN1B), and p57 (CDKN1C). The Cip/Kip family 
is well characterized for their role as negative regulators of G1 phase cell cycle 
progression by inhibiting a broad spectrum of cyclin-CDK complexes (Sherr and 
Roberts 1999). The INK4 family members include p16 and p14, (ARF encoding, 
CDKN2A/ARF), p15 (CDKN2B), p18 (CDKN2C), and p19 (CDKN2D). The INK4 
family inhibits the activity of CDK6 and CDK4 complexes. 
A germline mutation identified in CDKN1B, encoding p27, established the 
involvement of CDKI gene mutations in a MEN 1-like syndrome (Pellegata et al., 
2006). This discovery was later confirmed by other investigators (Malatore S., et. 
al. 2010, Martucci F, 2012), and led to the identification of variants in other 
CDKIs (Costa-Guda J., 2013). There are no established genotype-phenotype 
correlations between patients presenting with MEN1 syndrome due to mutations 
in the MEN1 gene or in the CDKI genes. For this reason, it is especially important 
to determine the underlying genetic cause in each patient who presents clinically 
with MEN1 syndrome features, so that potential genotype-phenotype correlations 
can be made, which may ultimately help guide treatment decisions. 
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Methods 
 One female patient with a diagnosis of phenotypic MEN1, based on a 
personal history of prolactinoma and familial hyperparathyroidism, but a normal 
MEN1 gene status was examined in this study. We received germline DNA and 
performed PCR and Sanger sequence analysis of four CDKI genes (CDKN2B, 
CDKN2C, CDKN1A, or CDKN1B), as previously described (Costa-Guda J., et. al 
2011, 2013). 
Results 
The four CDKI genes were analyzed and one sequence variant was 
identified. This novel c.34G>A variant was found in exon 2 of the CDKN2C gene. 
This heterozygous, missense mutation changes the first base of the codon, 
resulting in an amino acid change at position 12 from an alanine to threonine 
(Figure 14).  
Two methods were used to predict the functional effects of the CDKN2C 
variant. The polymorphism phenotyping V2 (Polyphen-2) software program was 
used for predicting the impact of an amino acid substitution on the structure and 
function of a human protein using physical and comparative considerations. The 
PolyPhen-2 score ranges from 0.0 (tolerated) to 1.0 (deleterious). Variants with 
scores of 0.0 are predicted to be benign. Values closer to 1.0 are more 
confidently predicted to be deleterious. The mutation was predicted to be 
probably damaging with a score of 0.983 out of 1.0. 
Prediction was verified using PROVEAN. PROVEAN scores equal to or 
below a predefined threshold (e.g. -2.5) are predicted to have a "deleterious" 
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effect, while scores above the threshold predict a "neutral" effect. The PROVEAN 
score for the identified mutation was -3.626, suggesting it as deleterious.  
 
 
Figure 14. CDKN2C gene Germline variant c.34G>A 
These chromatograms show a novel c.34G>A variant for the germline sequence. 
A mutation in the CDKNC gene was found at position 34, encoding a codon at 
amino acid position 12. This alters the codon from an alanine (GCA) to threonine 
(ACA) residue also, displaying heterozygosity [guanine/adenine]. 
 
 
Discussion 
In this study several cyclin dependent kinase inhibitors were analyzed in a 
patient with phenotypic MEN1 but normal MEN1 gene status. A novel variant 
c.34G>A, in CDKN2C, resulting in a p.A12T change in p18 protein, was found. 
The protein variant is predicted to have a "deleterious" effect by the software 
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program PROVEAN and polyphen-2. As expected for a germline mutation, this 
variant was heterozygous. This specific variant was not found in National Center 
of Biotechnology Information (NCBI), Catalogue of Somatic Mutations in Cancer 
(COSMIC), or in the single nucleotide polymorphism database (dbSNP).  
The evidence, pending confirmation, of the variant c.34G>A in CDKN2C 
contributing to the clinical phenotype of MEN1 syndrome would be strengthened 
by directly determining an abnormal impact of the mutation on CDKN2C activity. 
The significance of this finding can be verified through experiments that 
demonstrate a relationship between the genotype with the variant and the clinical 
phenotype by incorporating a cellular or animal model (Cassanova et al., 2014).   
Further studies, in which other affected and unaffected family members 
are examined is another way to strengthen the evidence of the CDKN2C 
mutation’s relevance. Concordance of the candidate genotype and clinical 
phenotype in family members of the patient would help demonstrate the 
relevance of the CDKN2C variant. However, the inability to identify this variant in 
family members with the same clinical manifestations would negate its 
significance (Cassanova et al., 2014).  
The germline DNA of a single patient was sequenced in order to identify 
any mutations in the CDKIs that could contribute to the molecular pathogenesis 
of this patient’s adenomas, linked to MEN1 syndrome. The Identification of a 
missense mutation in the CDKN2C gene could potentially suggest that it plays a 
role in the phenotypic presentation of the MEN1 syndrome. Further knowledge 
on this inherited mutation might be useful in the management of disease by 
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providing guidance for best course of action for treatment for others in the same 
family. The patients could benefit from a positive or negative status report. For 
instance, a positive status could direct them to the best monitoring and treatment 
options. On the other hand, individuals with a negative status will be spared from 
unnecessary screenings and checkups.  In general, an increased patient sample 
pool together, with powerful tools like Next Generation Sequencing technology, 
will assist in the discovery of more variants associated with parathyroid related 
diseases.  
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List of Abbreviations 
CASR  Calcium Sensing Receptor 
CCND1  Human Cyclin D1 proto-oncogene 
CDK  Cyclin dependent kinase 
CDKI  Cyclin dependent kinase inhibitor 
CDKN1A  Human cyclin dependent kinase inhibitor 1A gene, p21 
CDKN2A  Human cyclin dependent kinase inhibitor 1A gene, p16 
CDKN1B  Human cyclin dependent kinase inhibitor 1B gene, p27 
CDKN2B  Human cyclin dependent kinase inhibitor 2B gene, p15  
CDKN1C     Human cyclin dependent kinase inhibitor 1C gene, p57 
CDKN2C     Human cyclin dependent kinase inhibitor 2C gene, p18 
CDKN2D     Human cyclin dependent kinase inhibitor 2D gene, p19 
CTNNB1  Human catenin (cadherin-associated protein), beta 1 gene 
DNA  Deoxyribonucleic acid 
FHH  Familial hypocalciuric hypercalcemia 
HPT-JT  Hyperparathyroidism-jaw tumor syndrome 
HRPT2  Human Hyperparathyroidism 2 gene, encoding parafibromin 
(CDC73) 
MEN1  Multiple endocrine neoplasia type 1 
MEN1  Human multiple endocrine neoplasia type 1 gene 
MEN2  Multiple endocrine neoplasia type 2 
MEN2A  Multiple endocrine neoplasia type 2A 
MEN2B  Multiple endocrine neoplasia type 2B 
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MTC  Medullary thyroid cancer 
PCR  Polymerase chain reaction 
PTH  Parathyroid hormone 
RET  Human RET (rearranged during transfection) proto-oncogene 
SNP  Single nucleotide polymorphism 
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